×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GRFS – grifols, s.a. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GRFS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
02:30 am
grfs
Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors
Medium
Report
Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors
11/8
03:54 pm
grfs
Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors
Low
Report
Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors
10/31
07:30 am
grfs
Grifols, S.A. (NASDAQ: GRFS) was upgraded by analysts at Berenberg Bank to a "strong-buy" rating.
Low
Report
Grifols, S.A. (NASDAQ: GRFS) was upgraded by analysts at Berenberg Bank to a "strong-buy" rating.
10/29
08:00 am
grfs
Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution
Medium
Report
Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution
10/22
08:00 am
grfs
Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury
Low
Report
Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury
10/3
08:00 am
grfs
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
Low
Report
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
9/6
11:00 am
grfs
The Schall Law Firm Is Looking Into Grifols SA For Possible Securities Related Improprieties And Stockholders Are Invited To Reach Out
Low
Report
The Schall Law Firm Is Looking Into Grifols SA For Possible Securities Related Improprieties And Stockholders Are Invited To Reach Out
9/5
03:00 pm
grfs
Grifols Class B stock falls as Brookfield reportedly seeks lower price [Seeking Alpha]
Low
Report
Grifols Class B stock falls as Brookfield reportedly seeks lower price [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/19
03:14 pm
grfs
Form 6-K Grifols SA For: Nov 19
Low
Report
Form 6-K Grifols SA For: Nov 19
11/19
08:17 am
grfs
Form 6-K Grifols SA For: Nov 19
Low
Report
Form 6-K Grifols SA For: Nov 19
11/14
11:46 am
grfs
Form SC 13G/A Grifols SA Filed by: BRANDES INVESTMENT PARTNERS, LP
Low
Report
Form SC 13G/A Grifols SA Filed by: BRANDES INVESTMENT PARTNERS, LP
11/7
11:58 am
grfs
Form 6-K Grifols SA For: Nov 07
Low
Report
Form 6-K Grifols SA For: Nov 07
9/25
05:15 pm
grfs
Form 6-K Grifols SA For: Sep 25
Low
Report
Form 6-K Grifols SA For: Sep 25
9/23
05:11 pm
grfs
Form 6-K Grifols SA For: Sep 23
Low
Report
Form 6-K Grifols SA For: Sep 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/1
GRIFOLS S A/S (NASDAQ: GRFS) had its "hold" rating re-affirmed by analysts at Kepler Capital Markets.
7.5%
3/25 Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19 7.3%
3/27 Form 6-K Grifols SA For: Mar 27 5.5%
3/12 GRIFOLS S A/S (NASDAQ: GRFS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.0%
2/12 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $26.00 price target on the stock. 4.4%
3/10 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 3.9%
6/27 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. 2.3%
7/31 Form 6-K Grifols SA For: Jul 31 2.2%
10/29 GRIFOLS S A/S (NASDAQ: GRFS) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.2%
9/18 GRIFOLS S A/S (NASDAQ: GRFS) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 1.8%
3/25 Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19 7.3%
3/27 Form 6-K Grifols SA For: Mar 27 5.5%
3/12 GRIFOLS S A/S (NASDAQ: GRFS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.0%
2/12 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $26.00 price target on the stock. 4.4%
3/10 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 3.9%
6/27 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. 2.3%
7/31 Form 6-K Grifols SA For: Jul 31 2.2%
10/29 GRIFOLS S A/S (NASDAQ: GRFS) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.2%
9/18 GRIFOLS S A/S (NASDAQ: GRFS) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 1.8%
TOP News Decliners
4/21
Q1/2020 3/31/2020 EPS 0.270 ZacksConsensus N/A ActVsEst N/A - N/A
-4.2%
4/29 GRIFOLS S A/S (NASDAQ: GRFS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -3.6%
2/22 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -3.5%
12/9 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at Banco Sabadell from a "sell" rating to a "buy" rating. -3.3%
4/6 Form 20-F Grifols SA For: Dec 31 -3.2%
5/8 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -2.7%
8/3 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -2.5%
5/7 Q1/2019 3/31/2019 EPS 0.170 ZacksConsensus 0.250 ActVsEst (0.080) - Miss -2.0%
7/5 Form 6-K Grifols SA For: Jul 04 -1.8%
10/29 Form 6-K Grifols SA For: Oct 29 -1.7%
4/29 GRIFOLS S A/S (NASDAQ: GRFS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -3.6%
2/22 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -3.5%
12/9 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at Banco Sabadell from a "sell" rating to a "buy" rating. -3.3%
4/6 Form 20-F Grifols SA For: Dec 31 -3.2%
5/8 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -2.7%
8/3 GRIFOLS S A/S (NASDAQ: GRFS) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -2.5%
5/7 Q1/2019 3/31/2019 EPS 0.170 ZacksConsensus 0.250 ActVsEst (0.080) - Miss -2.0%
7/5 Form 6-K Grifols SA For: Jul 04 -1.8%
10/29 Form 6-K Grifols SA For: Oct 29 -1.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: